Veronique Debien, Medical Oncologist at Institut Bergonié, shared on LinkedIn:
“Looking forward to ESMO2026 in Madrid!
An exciting opportunity to discuss advances in early oncology drug development, particularly in ADCs, bispecific antibodies and biomarker-driven therapies.
At Institut Bergonié, our Early Phase Trials Unit is actively involved in first-in-human and phase I/II clinical trials, with several programs we contribute to presenting new data at this years congress.
I’ll be pleased to connect with colleagues and industry partners to discuss ongoing developments and explore opportunities for future clinical trial collaborations.
See you in Madrid!”
Other articles featuring Veronique Debien on OncoDaily.